A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2014
At a glance
- Drugs CX 157 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors CeNeRx BioPharma
- 01 May 2012 Actual end date (1 May 2012) added as reported by ClinicalTrials.gov.
- 01 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 31 May 2011 Planned end date changed from 1 Jul 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.